Karkinos Healthcare companions with US-based C2i Genomics to broaden AI most cancers detection


Share post:

Karkinos Healthcare, a technology-driven most cancers care platform in India, has entered right into a strategic partnership with American oncology diagnostics agency C2i Genomics to advertise AI-enabled most cancers monitoring within the nation.

In accordance with a press assertion, their partnership will broaden minimal residual illness (MRD) monitoring throughout Karkinos’ community utilizing C2i Genomics’ whole-genome evaluation platform. MRD refers back to the small variety of most cancers cells remaining in a affected person’s physique after remedy.

Karkinos operates a distributed most cancers care community mannequin, coordinating healthcare establishments and professionals to ship streamlined entry to most cancers care. It’s at the moment current in some places throughout eight Indian states and in India’s Nationwide Capital Area. 


Over the previous decade, India noticed its variety of new most cancers instances rise by a fifth, leaping from 18.7 million in 2010 to 23 million in 2019. Most cancers deaths additionally rose by over 1 / 4 to 10 million. These rising figures recommend a necessity for higher most cancers detection and remedy choices for the Indian inhabitants, in line with C2i Genomics. 

The diagnostics firm gives the C2inform MRD check which identifies hint quantities of recurrent most cancers. A blood pattern is analysed by means of cloud-based software program that makes use of AI to detect most cancers recurrence or resistance “a lot earlier and at far decrease ranges” than different present applied sciences out there.

Karkinos will arrange C2i’s MRD check at its Superior Heart for Most cancers Diagnostics and Analysis in Kochi.


Karkinos provides to the rising checklist of C2i Genomics’ companions who adopted its MRD monitoring platform, together with Singaporean biotech firm NovogeneAIT Genomics and NuProbe, a genomics firm that additionally operates in China. The corporate simply acquired a CE mark for its MRD check in April.

Final month, Karkinos reported that the American tutorial medical centre Mayo Clinic has taken a minority stake within the firm for an undisclosed quantity.


“At Karkinos, we’re combining best-in-class oncology experience with advances in expertise and biosciences to advertise early detection of most cancers,” mentioned Karkinos CEO and founder Ramachandran Venkataramanan.

“Karkinos Healthcare shares in our imaginative and prescient to extend [the] entry to distributed most cancers monitoring and will probably be instrumental in advancing our commercialisation efforts to carry the C2inform MRD check to labs throughout India,” C2i Genomics CEO and co-founder Asaf Zviran additionally commented.

Supply hyperlink


Please enter your comment!
Please enter your name here


Related articles